Fig 1.
PRISMA flowchart for inclusion and exclusion of Oropouche virus literature.
Table 1.
Human study characteristics (author, year, location, population, sample size etc).
Fig 2.
Reported pooled seroprevalence from studies sampling participants with febrile illness or suspected of Oropouche infection in 2000 to 2024.
Seroprevalence is displayed as a proportion with 95% confidence intervals in square brackets.
Fig 3.
Reported pooled seroprevalence from studies sampling participants among asymptomatic general populations in 2000 to 2024.
Seroprevalence is displayed as a proportion with 95% confidence intervals in square brackets.
Table 2.
Meta-regression of seroprevalence from studies sampling participants in 2000 to 2024, n = 38.
Fig 4.
Reported pooled viral prevalence from studies sampling participants in 2000 to 2024, n = 61.
Seroprevalence is displayed as a proportion with 95% confidence intervals in square brackets.
Table 3.
Summary of vector study characteristics.